Drug Approval | December 31, 2022
USFDA grants appeal for Ardelyx's XPHOZAH
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Cipla and Ethris partner for the development of mRNA-based therapies
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Modi stressed the need to ensure that the entire Covid infrastructure at all levels is maintained at a high level of preparedness in terms of equipment, processes, and human resources
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Post the sale, Patel family has become the single largest promoter shareholder in the company
UHI is envisioned as a foundational layer of the Ayushman Bharat Digital Mission and aims to enable interoperability in health services in India through open protocols
LG Chem will receive totaling up to $95.5 million for the China rights
He is a seasoned leader with 34 years of rich and diverse experience across geographies and consumer facing companies such as Xerox India and Bharti Airtel
The hospital is being developed at a cost of more than Rs. 1,575 crore
Subscribe To Our Newsletter & Stay Updated
